Syngene International Ltd. · NSE:SYNGENE
Syngene International — Q1 FY23 Earnings Presentation
40 slides from Syngene International's earnings presentation, Jul 20, 2022
Slide 1: Regulation 30 cover letter to stock exchanges
Ref: Syn/CS/SE/IP/2022-23/July/10 Syngene International Limited Biocon SEZ, Biocon Park, Plot No. 2 & 3, Bommasandra Industrial Area, IV Phase, Jigani Link Road, Bengaluru 560099, Karnataka, India. T +91 80 6891 8000 F +91 80 6891 8808 CIN: L85110KA1993PLC014937 www.syngeneintl.com July 20, 2022 To,
Slide 2: Investor Presentation July 2022
Investor Presentation July 2022
Slide 3: Safe harbour
Safe harbour Certain statements in this release concerning our future growth prospects are forward-looking statements, which are subject to a number of risks, uncertainties and assumptions that could cause actual results to differ materially from those contemplated in such forward-looking statements
Slide 4: Contents
Contents 1 Operating Highlights 2 Syngene – Putting Science to Work 3 Strategic Advantages 4 Financials 5 Shareholding and Share Information Putting Science to Work 3
Slide 5: Operating Highlights
Ml Operating Highlights Syngene
Slide 6: Q1 FY23 performance
Q1 FY23 performance Operating Highlights Q1 Financial Highlights • Strong underlying performance across all business divisions The first quarter results are against a strong quarter last year due to sales of remdesivir. Excluding the impact of remdesivir, the underlying revenue from • The contributi
Slide 7: Syngene signs 10 year manufacturing deal with Zoetis worth up to $500Mn
Syngene signs 10 year manufacturing deal with Zoetis worth up to $500Mn Revenue: • Marks an inflection point for Syngene’s Development and Manufacturing Services Division • At full capacity utilization, Biologics business is expected to generate an asset turnover of about 1x • Will position Syngene
Slide 8: Revised FY23 guidance: upgraded revenue growth from mid teens to high teens
Revised FY23 guidance: upgraded revenue growth from mid teens to high teens Parameter FY23 Guidance (April 2022) Revised FY23 Guidance (July 2022) Revenue from operations Mid-teen growth High- teen growth EBITDA Margin EBITDA margin around 30%. EBITDA margins around 30% PAT* Growth PAT growth rate f
Slide 9: Syngene – Putting Science to Work
2 Syngene – Putting Science to Work
Slide 10: Partner in innovation: #Puttingsciencetowork
Partner in innovation: #Puttingsciencetowork Who we are and what we do Working with innovators from around the world to find solutions to their scientific challenges Integrated solution Covering pharma, biotech, Innovative culture driven Well established in scientific provider across nutrition, anim
Slide 11: Key facts and figures
Key facts and figures 420+ 15 400+ World class active clients collaborations Patents infrastructure with top 20 pharmaceutical held with clients of 2 Mn sq. ft. qualified to companies meet international standards Rs. 39,435 Mn Rs. 26,570 Mn Rs. 4,211 Mn 87% (US$526Mn*) (US$354Mn*) (US$56Mn*) Talente
Slide 12: International accreditations
International accreditations • USFDA,OHSAS 18001, • GLP, cGMP, AAALAC & CPCSEA Certified Facilities • CAP accreditation, ISO/IEC 27001:2013 accreditation • EMA and PMDA approved, AAALAC Accredited facility • The safety assessment laboratories and large molecule bioanalytical lab are ISO IEC 17025:20
Slide 13: Our experience spans multiple industry segments and partnerships with global leaders
Our experience spans multiple industry segments and partnerships with global leaders across the world Large & Emerging Animal Consumer Mid-Sized BioPharma Universities AgroChem Health products BioPharma (EBP) Clinical-stage company creating novel medicines targeting G protein-coupled receptors Globa
Slide 14: Our journey so far
Our journey so far 2019 – 2022 Continued investments and Globalization and strategic collaboration • Expanded into formulations development growth • Contract with Endo Pharmaceuticals to develop novel anti cancer • Expanded collaboration with BMS; biological therapeutic molecules Baxter Amgen and Zo
Slide 15: Our span across the value chain, making us one-stop solution provider
Our span across the value chain, making us one-stop solution provider enabling us to capture the opportunity Research business Development and Manufacturing business Discovery Services Dedicated R&D Centers Development Services Manufacturing Services Flexible Platform with capability Ring-fenced inf
Slide 16: Our collaboration models
Our collaboration models 1 2 3 4 5 6 Dedicated R&D Labs FTE FFS Productivity based model Risk-reward Delivery based contract for CDMO business • Dedicated scientific • Pre-defined numbers • Client collaboration to • Offer the services • Across a portfolio of and support teams of scientific personnel
Slide 17: Backed by world class state of the art infrastructure
Backed by world class state of the art infrastructure HQ Campus 90 acres in Bangalore where most of Syngene’s R&D Expansion Genome capabilities are Valley, Hyderabad, India housed today commenced operation in Aug 2019 API Manufacturing Expansion Commercial Manufacturing to Biologics Expansion suppor
Slide 18: Agile and experienced workforce; Building capabilities and careers to sustain growth
Agile and experienced workforce; Building capabilities and careers to sustain growth ~6000 Environment that engages our employees and enables them to grow strong total headcount Nurturing fresh • Syngene Training Academy (STA) offers recruits a six-month extended induction to help them understand ta
Slide 19: Operational robustness driving strategy execution
Operational robustness driving strategy execution Established model of continuous improvement driven by certified operational leaders Expansion of footprint and organization wide Six Sigma Black Belt certified staff in each service line and capabilities to support growth support functions Lab space
Slide 20: Strategic Advantages
3 Strategic Advantages Syngene
Slide 21: Syngene’s Strength
Syngene’s Strength Quality Focus • Quality driven organization A Global CRO/CDMO IP Position • Excellent track record of compliance with • Integrated Drug Discovery, Development and • IP can be fully assigned to clients global regulators Manufacturing service provider • Strong track record of Data I
Slide 22: Strong track record of growth and profitability
Strong track record of growth and profitability Total Revenue (Rs. Mn) EBITDA (Rs. Mn) Profit Before Tax * (Rs. Mn) FY18 to FY22 - CAGR 16% FY18 to FY22 - CAGR 13% FY18to FY18 toFY22 FY22--CAGR CAGR8% 8% 8,489 26,570 7,364 5,151 6,995 22,489 6,119 4,456 4,342 20,935 4,154 19,007 5,266 3,725 14,849 F
Slide 23: Multiple levers for growth going ahead
Multiple levers for growth going ahead Expand/Extend Existing Clients Capacity Expansion • High service integration • Consistent investment • Dedicated centers model • FTE services, manufacturing, formulation, biologics, stability Engage New Clients • Tailored service offerings and dedicated personn
Slide 24: Our end-to-end platform enables a one-stop-shop for discovery, development and manufacturing
Our end-to-end platform enables us to be a 'one-stop-shop' for discovery, development and manufacturing (small and large molecules) Discovery Development Manufacturing Small Drug Substance Chemistry Molecules Large Development Clinical Supplies Molecules Drug Product Development Biology Integrated D
Slide 25: Discovery Services
Discovery Services Target Identification and Hit HitHit to Lead to Lead Optimization Lead IND Enabling IND IND IND / Ph1 / DE Validation Identification Lead Optimization Enabling Ph1 DE Target ID In vitro assays: In In vitro vitro assays: assays: In Invivo vivoassays/studies: assays/studies: Later T
Slide 26: Development Services and Manufacturing Services
Development Services and Manufacturing Services Developability Development Clinical Phase Registration/process Commercial Assessment phase Phase I Phase II Phase III validation batches Early PK, MTD/DRF studies, • IND enabling GLP Tox studies: Ames, Chromosomal • NDA enabling studies: Sub- chronic a
Slide 27: Biologics Development and Manufacturing services
Biologics Development and Manufacturing services Developability Development Clinical Phase Registration/process Commercial Assessment phase Phase I Phase II Phase III validation batches • Cell line development / • Clone to GMP • Process DOE, robustness and safety study selection • Upstream process O
Slide 28: Led by a globally experienced management team
Led by a globally experienced management team Jonathan Hunt Sibaji Biswas Dr. Mahesh Bhalgat Ashu Tandon Sanjeev Sukumaran Managing Director and Chief Chief Financial Officer Chief Operating Officer Chief Commercial Officer Chief Human Resources Officer Executive officer Vodafone, Sanofi, Amgen, IQV
Slide 29: Advised by Our Board of Directors
Advised by Our Board of Directors Kiran Mazumdar Shaw Jonathan Hunt Dr. Carl Dcicco Professor Catherine Vinita Bali Non-Executive Managing Director and Chief Independent Director Rosenberg Independent Director Chairperson Executive officer Non-Executive Director Experience Chairperson of Biocon Limi
Slide 30: Committed to sustainability
Committed to sustainability Safety is at the heart of everything we do Committed to environmental protection • Accredited with ISO 45001:2018 for its Occupational Health and Safety • Accredited with ISO 14001:2015 for its effective Environment (OH&S) measures Management System (EMS) • Risk assessmen
Slide 31: Industry recognition for scientific capability and best practices
We have consistently received industry recognition for our scientific capability and best practices • Bio-Excellence Award 2018: At Bengaluru Tech • CMO Leadership Award Winner 2020 - under • CMO Leadership Awards 2022 Received 6 awards for all Summit, Bengaluru Categories: Capabilities, Compatibili
Slide 32: Proactively managing risks through robust risk management framework
Proactively managing risks through robust risk management framework Syngene has a risk management framework to identify, monitor, report and manage risk across the business. Every risk owner monitors and manages risks relevant to their area of responsibility. Executive Committee (EC) Board of Direct
Slide 33: Financials
4 Financials
Slide 34: Q1 financial highlights
Q1 financial highlights Particulars Q1 FY23 Q1 FY22 YoY Change Q4 FY22 QoQ change Revenue from Operations 6,445 5,945 8% 7,581 (15%) Other Income 155 123 26% 147 6% Total Revenue 6,600 6,068 9% 7,728 (15%) Material and Power Costs 1,791 2,082 (14%) 2,325 (23%) Employee Costs 1,861 1,711 9% 1,736 7%
Slide 35: FY22 financial highlights
FY22 financial highlights Particulars FY22 FY21 YoY Change Balance Sheet Highlights Revenue from operations (excl export incentives) 26,042 21,843 19% Other Income 528 646 (18%) Total Revenue 26,570 22,489 18% As on 31st March 2022 Material and power costs 8,138 5,839 39% Employee costs 7,181 6,602
Slide 36: Shareholding and Share Information
Shareholding and Share 5 Information
Slide 37: Biocon Group and Syngene
Biocon Group and Syngene Biocon Limited, founded in 1978, is Syngene, a subsidiary of Biocon Limited, was Biocon Biologics, another subsidiary of an innovation-led global established in 1993 as India’s first Contract Biocon Limited, consolidates the biopharmaceuticals company Research Organization -
Slide 38: Shareholding and Share Information
Shareholding and Share Information Syngene’s Shareholding Pattern* Syngene’s Share Information* NSE Ticker SYNGENE 1% BSE Ticker 539268 Promoter & 29% Promoter Group Market Cap (Rs. Mn) 2,22,342 Public % free-float 29% Free-float market cap (Rs. Mn) 64,326 ESOP Trust 70% Share Outstanding (Mn) 401 3
Slide 39: For more details
For more details Visit our website www.syngeneintl.com https://twitter.com/SyngeneIntl https://www.linkedin.com/company/syngene-international-limited https://www.facebook.com/syngeneintl/ https://www.youtube.com/channel/UCIC4WSA1k5YAC531gMLkbIQ IR Contact: Media Contact: Krishnan G Shotorupa Ghosh +
Slide 40: Thank you
Thank you © 2022 Syngene International Limited, Bengaluru, India. All Rights Reserved. Syngene believes the information in this document is accurate as of its publication date; such information is subject to change without notice. Syngene acknowledges the proprietary rights of other companies to the
Syngene International — Q1 FY23 Earnings Presentation on 6ix